{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:10Z","timestamp":1790878330699,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP J33C22002920006"],"award-info":[{"award-number":["CUP J33C22002920006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005969","name":"Alma Mater Studiorum University of Bologna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105897","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:27:49Z","timestamp":1763638069000},"page":"105897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 \u226550%"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"De Giglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Soldato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.G.","family":"Dall\u2019Olio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mantuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sperandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Favorito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sadowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gorria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mezquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tabb\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.esmoop.2025.105897_bib1","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10183","key":"10.1016\/j.esmoop.2025.105897_bib2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"10274","key":"10.1016\/j.esmoop.2025.105897_bib3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105897_bib4","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105897_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105897_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","article-title":"Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis","volume":"177","author":"Viscardi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105897_bib7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00262-024-03836-w","article-title":"Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy","volume":"73","author":"De Giglio","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmoop.2025.105897_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105897_bib9","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105897_bib10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105897_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105897_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jnci\/djac205","article-title":"Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: a meta-analysis","volume":"115","author":"Di Federico","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2025.105897_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103302","article-title":"PD-1\/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression \u2265 50%: selecting the best strategy","volume":"160","author":"Di Federico","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2025.105897_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.10.008","article-title":"Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study","volume":"150","author":"Bersanelli","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105897_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105897_bib16","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.3390\/cancers14235845","article-title":"The palliative prognostic (PaP) score without clinical evaluation predicts early mortality among advanced NSCLC patients treated with immunotherapy","volume":"14","author":"De Giglio","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105897_bib17","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1556-0864(25)00211-4","article-title":"Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1","volume":"20","author":"Garassino","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105897_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108058","article-title":"STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status","volume":"199","author":"De Giglio","year":"2025","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105897_bib19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/biom13121803","article-title":"Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond","volume":"13","author":"Mosca","year":"2023","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105897_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105897_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","article-title":"Precision immunotherapy for STK11\/KEAP1-mutant NSCLC","volume":"19","author":"Ricciuti","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105897_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41467-023-36328-z","article-title":"Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer","volume":"14","author":"Hong","year":"2023","journal-title":"Nat Commun"},{"issue":"8038","key":"10.1016\/j.esmoop.2025.105897_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105897_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41698-024-00765-w","article-title":"Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images","volume":"8","author":"Patkar","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105897_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-24-1993","article-title":"Metabolic tumor volume assessed by 18F FDG-PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates","volume":"31","author":"Dall\u2019Olio","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105897_bib26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/14712598.2022.2116273","article-title":"Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives","volume":"22","author":"Cella","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105897_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/imt-2020-0280","article-title":"PD-L1 \u2265 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination","volume":"13","author":"Gelsomino","year":"2021","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105897_bib28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2025.105897_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/PO.20.00021","article-title":"Comparison of fast-progression, hyperprogressive disease, and early deaths in advanced non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors or chemotherapy","volume":"4","author":"Ferrara","year":"2020","journal-title":"JCO Precis Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:51:30Z","timestamp":1773327090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017661"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105897","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 \u226550%","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105897"}}